<DOC>
	<DOCNO>NCT00709657</DOCNO>
	<brief_summary>Age relate macula degeneration one common sight threaten disease elderly . The call wet form AMD cause choroidal neovascularisation ( CNV ) pathological vessel , lead leakage , bleed macular edema . Several line evidence suggest vascular endothelial growth factor ( VEGF ) play key role induction CNV . Recent evidence indicate overexpression VEGF retinal pigment epithelium may lead development CNV experimental model , intravitreal injection VEGF blocker prevents development experimental CNV . This hypothesis also support promising effect anti-VEGF treatment patient choroidal neovascularisation . The substance currently clinical use include ranibizumab ( Lucentis® ) , bevacizumab ( Avastin® ) pegaptanib ( Macugen® ) . However , physiological point view , VEGF also serve survival factor exist vessel neuronal cell . Moreover , report VEGF induces vasodilatation , probably increase production nitric oxide . Accordingly one may hypothesize anti-VEGF treatment associate ocular vasoconstriction unknown long term result . Thus , current study , investigator set investigate whether ocular perfusion affect single intravitreal anti-VEGF .</brief_summary>
	<brief_title>The Effect Single Intravitreal Anti-VEGF Therapy Optic Nerve Head Perfusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>40 subject ≥ 50 year age Subjects angiographic subtypes neovascular wet AMD , already schedule intravitreal antiVEGF therapy one eye Good central eccentric fixation History previous AntiVEGF therapy History previous intravitreal injection drug Intraocular pressure ≥ 25 Glaucoma History presence thromboembolic event Diabetes mellitus Blood donation previous 3 week Ametropy ≥ 6 dpt</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>anti-VEGF</keyword>
</DOC>